(Q40942602)

25 September 2017

1 reference

title

Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis (English)

1 reference

25 September 2017

1 reference

Schmitt M

1

1 reference

25 September 2017

Wilhelm O

2

1 reference

25 September 2017

Jänicke F

3

1 reference

25 September 2017

Magdolen V

4

1 reference

25 September 2017

Reuning U

5

1 reference

25 September 2017

Ohi H

6

1 reference

25 September 2017

Moniwa N

7

1 reference

25 September 2017

Kobayashi H

8

1 reference

25 September 2017

Weidle U

9

1 reference

25 September 2017

Graeff H

10

1 reference

25 September 2017

publication date

1 April 1995

1 reference

Journal of obstetrics and gynaecology (Tokyo, Japan)

25 September 2017

published in

1 reference

25 September 2017

volume

21

1 reference

25 September 2017

issue

2

1 reference

25 September 2017

page(s)

151-165

1 reference

Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.1995.TB01089.X

Prevention of metastasis by inhibition of the urokinase receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.1995.TB01089.X

Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.1995.TB01089.X

Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.1995.TB01089.X

Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.1995.TB01089.X

Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.1995.TB01089.X

Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.1995.TB01089.X

A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.1995.TB01089.X

Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.1995.TB01089.X

A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.1995.TB01089.X

How to use prognostic factors in axillary node-negative breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.1995.TB01089.X

Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.1995.TB01089.X

Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.1995.TB01089.X

Physiological consequences of loss of plasminogen activator gene function in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.1995.TB01089.X

Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0756.1995.TB01089.X

10.1111/J.1447-0756.1995.TB01089.X

21 January 2018

Identifiers

DOI

1 reference

25 September 2017

1 reference